Live News EQUITY FLASH M impact Nov 17, 2026, 09:15 PM UTC Merck discontinues Phase 3 BELLWAVE-011 trial after EDMC review MRK SquawkNews Desk 1 updates Updated Nov 17, 2026, 09:16 PM UTC Story updates 09:16:30 PM UTC SquawkNews Merck halts nemtabrutinib development after trial review flags unfavorable risk-benefit profile